ELATIVE
LIVE

Serial Number

79324525

Owner

GENFIT

Attorney

Ronald M. Kachmarik

Filing Date

Jun 25, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ELATIVE Trademark

Serial Number: 79324525 • Registration: 6854744

ELATIVE is a trademark filed by GENFIT on June 25, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

GENFIT (42 trademarks)

885 rue Eugene Avinee
Loos 59120 , FR

Entity Type: 03

Trademark Details

Filing Date

June 25, 2021

Registration Date

September 27, 2022

Published for Opposition

July 12, 2022

Goods & Services

Pharmaceutical preparations for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases, gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; organic biological preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; diagnostic preparations for medical use; diagnostic reagents for medical use

Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical products, in particular conducting clinical trials for others for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely providing information, results and data relating to scientific or medical research and development of pharmaceutical products, especially from an online searchable database; medical and scientific research, namely conducting clinical trials for others; pharmaceutical and biological development and research services for third parties; clinical research for others in the field of pharmaceuticals and medicines; evaluation of the efficacy of pharmaceutical products

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 19, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 14, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 25, 2023 FICS
FINAL DISPOSITION PROCESSED
Jan 25, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 27, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 27, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 27, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Jul 19, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 12, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 12, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 29, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 29, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 22, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 9, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 8, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 7, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 7, 2022 TROA
REFUSAL PROCESSED BY IB
May 25, 2022 RFNT
NEW REPRESENTATIVE AT IB RECEIVED
May 8, 2022 NREP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 4, 2022 RFCS
REFUSAL PROCESSED BY MPU
May 4, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 25, 2022 RFCR
NON-FINAL ACTION WRITTEN
Mar 24, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 17, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 12, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 8, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 5, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 28, 2021 REPR